ProteoMediX: Prostate's PI3K biomarkers

ProteoMediX PI3K blood test seeks to avoid unneeded biopsies for prostate cancer

ProteoMedix AG is developing a multiplexed ELISA-based blood test that aims to confirm an initial PSA positive result and reduce unneeded biopsies by monitoring a quartet of biomarkers associated with alterations in PI3K signaling, a common underlying cause of prostate cancer. The company believes its ELISA could have an advantage over competing tests because it measures the activity of a tumor suppressor that has been directly linked to disease development.

While the effectiveness of PSA testing as a screening tool remains a topic of intense debate, there is widespread agreement that new diagnostics are

Read the full 930 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE